UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  April 30, 2015

 


 

ACCURAY INCORPORATED

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of incorporation)

 

001-33301

 

20-8370041

(Commission File Number)

 

(IRS Employer Identification No.)

 

1310 Chesapeake Terrace
Sunnyvale, California 94089

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (408) 716-4600

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02. Results of Operations and Financial Condition.

 

On April 30, 2015, Accuray Incorporated (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2015.  A copy of the Company’s press release dated April 30, 2015, titled “Accuray Reports Financial Results for Third Quarter of Fiscal Year 2015” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Number

 

Description

99.1

 

Press Release dated April 30, 2015, titled “Accuray Reports Financial Results for Third Quarter of Fiscal Year 2015”

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ACCURAY INCORPORATED

 

 

 

Dated: April 30, 2015

By:

/s/ Gregory Lichtwardt

 

 

Gregory E. Lichtwardt

 

 

Executive Vice President, Operations &
Chief Financial Officer

 

3



 

EXHIBIT INDEX

 

Number

 

Description

99.1

 

Press Release dated April 30, 2015, titled “Accuray Reports Financial Results for Third Quarter of Fiscal Year 2015”

 

4


Exhibit 99.1

 

 

Doug Sherk

Investor Relations, EVC Group

+1 (415) 652-9100

dsherk@evcgroup.com

Beth Kaplan

Public Relations Director, Accuray

+1 (408) 789-4426

bkaplan@accuray.com

 

Accuray Reports Financial Results for Third Quarter of Fiscal Year 2015

 

SUNNYVALE, Calif., April 30, 2015 — Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the third fiscal quarter and nine months ended March 31, 2015.

 

Third Quarter Highlights

 

·                  Gross orders grew 15 percent year-over-year or 21 percent on a constant currency basis

·                  Total revenue remained approximately flat at $97.5 million year-over-year but increased 5 percent on a constant currency basis

·                  Continued expansion of service gross profit margins to 38.4 percent

·                  Achieved positive operating income

·                  Adjusted EBITDA reached $9.9 million

 

“Year-over-year gross order growth was restored in the third quarter, but our overall gross order volume during the period did not fully meet our internal objectives, particularly in the U.S.,” said Joshua H. Levine, president and chief executive officer of Accuray.  “At the same time, our operating results were relatively solid with good revenue volume, expanding margins, controlled expenses and an operating profit for the first time in many years.”

 

Mr. Levine continued, “During the past few weeks, we have completed a thorough assessment of our execution on our five core strategies for driving consistent growth.  We have concluded that we still have more work ahead of us to build a stronger U.S. funnel, however we met or exceeded our expectations on strategies related to emerging markets, installed base satisfaction and TomoTherapy® System positioning, all of which demonstrate that we have many pieces in place to achieve our growth objectives and build shareholder returns.”

 

Financial Highlights

 

Gross product orders totaled $51.9 million for the 2015 fiscal third quarter, an increase of $6.7 million or 15 percent from the third quarter of the prior fiscal year.  On a constant currency basis, gross product orders for the fiscal third quarter were $54.5 million.  Ending product backlog was $347.4 million or approximately 2 percent lower than backlog at the end of the prior fiscal year third quarter.  Units in backlog have increased 10 percent year over year and on a constant currency backlog dollars have increased $12 million.

 

Total revenue was $97.5 million, which was relatively flat from the prior fiscal year third quarter and an increase of 5 percent on a constant currency basis.  The Americas region total revenues were $52.6 million, an increase of 63 percent from the prior fiscal year third quarter.  Total revenues outside the Americas region were $44.9 million, a decrease of 31 percent from the prior fiscal year third quarter.  Product revenues totaled $46.4 million and represented a decrease of 1 percent from the fiscal 2014 third quarter while service revenues totaled $51.2 million, an increase of 2 percent over last year’s fiscal year third quarter.

 

1



 

Total gross profit for the third quarter of fiscal 2015 was $38.7 million or 40 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 38 percent.  This compares to total gross margin of 41 percent, product gross margin of 46 percent and service gross margin of 36 percent for the prior fiscal year third quarter.  Total gross margin for the third quarter of fiscal 2015 was 42 percent on a constant currency basis as compared to 41 percent the prior year period.

 

Operating expenses were $37.5 million, reflecting a decrease of 7 percent compared with $40.2 million in last fiscal year’s third quarter.   The decrease was primarily due to lower incentive compensation and consulting expenses partially offset by higher legal fees.

 

Net loss was $3.0 million, or $0.04 per share for the third quarter of fiscal 2015, compared to a net loss of $4.7 million, or $0.06 per share, for the fiscal 2014 third quarter.

 

Adjusted EBITDA for the third quarter of 2015 was $9.9 million, compared to $7.8 million in the prior fiscal year third quarter.

 

Cash, cash equivalents, and investments were $149.6 million as of March 31, 2015, a decrease of $1.2 million from December 31, 2014.

 

Nine Month Highlights

 

For the nine months ended March 31, 2015, total revenue reached $278.1 million, representing an increase of 4 percent, or 7 percent on a constant currency basis, from the comparable period of fiscal year 2014.  Product revenue for the nine month period was $127.0 million, representing an increase of 4 percent while service revenue was $151.0 million, also representing 4 percent growth over the comparable prior fiscal year period.

 

Gross profit margin for the nine months ended March 31, 2015 was 38 percent, comprised of product gross margin of 41 percent and service gross margin of 35 percent.  This compares to total gross margin of 39 percent for the comparable prior fiscal year period.  Total gross margin for the nine months ended March 31, 2015 would have been 39 percent on a constant currency basis as compared to the comparable prior fiscal year period.

 

Operating expenses were $122.6 million for the nine months ended March 31, 2015, compared with $117.8 million in the fiscal 2014 comparable period.

 

Net loss for the nine months ended March 31, 2015 was $34.6 million, or $0.44 per share, compared to a net loss of $25.6 million, or $0.34 per share, for the comparable prior fiscal year period.

 

Adjusted EBITDA for the nine months ended March 31, 2015 was $5.1 million, compared to   $10.8 million in the comparable prior fiscal year period.

 

2015 Financial Guidance

 

Accuray is revising financial guidance for fiscal year 2015 as follows:  total revenue of $375 million to $385 million and adjusted EBITDA of $13 million to $16 million.  This compares to previously issued guidance updated most recently in January 2015 of $390 million to $410 million in revenue and $18 million to $27 million in adjusted EBITDA.  This revision is caused primarily by the effects of foreign currency on reported results.  The company reiterates that gross order growth in the second half of the fiscal year 2015 is expected to be greater than market growth.

 

2



 

Conference Call Information

 

Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results.  Conference call dial-in information is as follows:

 

·                  U.S. callers: (855) 798-3048

·                  International callers: (262) 912-4764

 

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the company’s website, www.accuray.com.  In addition, a dial-up replay of the conference call will be available beginning April 30, 2015 at 5:00 p.m. PT/8:00 p.m. ET and ending May 8, 2015.  The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International).

 

Use of Non-GAAP Financial Measures

 

The company has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation (“adjusted EBITDA”).  Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results.  A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.

 

The company presents certain measures, such as period-over-period revenue growth, on a constant currency basis, which excludes the effects of foreign currency translation.  Due to the continuing strengthening of the U.S. dollar against foreign currencies and the overall variability of foreign exchange rates from period to period, management uses these measures on a constant currency basis to evaluate period-over-period operating performance.  Measures presented on a constant currency basis are calculated by translating current period results at prior period monthly average exchange rates.

 

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP.

 

About Accuray

 

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives.  The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

 

Safe Harbor Statement

 

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements in this press release relate, but are not limited, to the company’s future results of operations, including management’s expectations regarding growth in gross orders, gross profit margins, revenues and adjusted EBITDA, ability to meet financial targets, and Accuray’s leadership position in radiation oncology innovation and technologies.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company’s ability to convert backlog to revenue; the success of the adoption of our CyberKnife and TomoTherapy Systems; the company’s ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K, which was filed on August 29, 2014, the company’s reports on Form 10-Q which were filed on

 

3



 

November 7, 2014 and February 6, 2015, and as updated periodically with the company’s other filings with the SEC.

 

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events.  The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not put undue reliance on any forward-looking statements.

 

###

 

Financial Tables to Follow

 

4



 

Accuray Incorporated

Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

Nine Months Ended
March 31,

 

 

 

2015

 

2014

 

2015

 

2014

 

 

 

 

 

 

 

 

 

 

 

Gross Orders

 

$

51,891

 

$

45,168

 

$

182,915

 

$

188,860

 

Net Orders

 

35,937

 

38,622

 

109,693

 

158,051

 

Order Backlog

 

347,408

 

353,621

 

347,408

 

353,621

 

 

 

 

 

 

 

 

 

 

 

Net revenue:

 

 

 

 

 

 

 

 

 

Products

 

$

46,361

 

$

47,045

 

$

127,026

 

$

121,761

 

Services

 

51,154

 

50,099

 

151,025

 

145,658

 

Total net revenue

 

97,515

 

97,144

 

278,051

 

267,419

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

Cost of products

 

27,332

 

25,255

 

75,168

 

68,836

 

Cost of services

 

31,523

 

32,185

 

97,933

 

94,230

 

Total cost of revenue

 

58,855

 

57,440

 

173,101

 

163,066

 

Gross profit

 

38,660

 

39,704

 

104,950

 

104,353

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

12,836

 

13,763

 

40,902

 

40,148

 

Selling and marketing

 

12,987

 

15,310

 

46,763

 

44,026

 

General and administrative

 

11,665

 

11,106

 

34,976

 

33,656

 

Total operating expenses

 

37,488

 

40,179

 

122,641

 

117,830

 

Income (loss) from operations

 

1,172

 

(475

)

(17,691

)

(13,477

)

Other expense, net

 

(3,618

)

(3,312

)

(14,607

)

(9,547

)

Loss before provision for income taxes

 

(2,446

)

(3,787

)

(32,298

)

(23,024

)

Provision for income taxes

 

521

 

878

 

2,311

 

2,615

 

Net loss

 

$

(2,967

)

$

(4,665

)

$

(34,609

)

$

(25,639

)

 

 

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(0.04

)

$

(0.06

)

$

(0.44

)

$

(0.34

)

Weighted average common shares used in computing loss per share:

 

 

 

 

 

 

 

 

 

Basic and diluted

 

78,746

 

76,382

 

77,981

 

75,447

 

 

5



 

Accuray Incorporated

Consolidated Balance Sheets

(in thousands)

(Unaudited)

 

 

 

March 31,

 

June 30,

 

 

 

2015

 

2014

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

95,449

 

$

92,346

 

Investments

 

54,185

 

79,553

 

Restricted cash

 

2,858

 

1,492

 

Accounts receivable, net

 

61,376

 

72,152

 

Inventories

 

109,705

 

87,752

 

Prepaid expenses and other current assets

 

15,650

 

17,873

 

Deferred cost of revenue

 

8,743

 

13,302

 

Total current assets

 

347,966

 

364,470

 

Property and equipment, net

 

29,856

 

34,391

 

Goodwill

 

58,020

 

58,091

 

Intangible assets, net

 

17,552

 

23,517

 

Deferred cost of revenue

 

1,752

 

2,899

 

Other assets

 

8,513

 

11,820

 

Total assets

 

$

463,659

 

$

495,188

 

Liabilities and equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

13,656

 

$

15,639

 

Accrued compensation

 

19,530

 

32,569

 

Other accrued liabilities

 

20,151

 

24,464

 

Customer advances

 

18,951

 

19,804

 

Deferred revenue

 

93,500

 

92,093

 

Total current liabilities

 

165,788

 

184,569

 

Long-term liabilities:

 

 

 

 

 

Long-term other liabilities

 

10,454

 

6,593

 

Deferred revenue

 

9,946

 

9,866

 

Long-term debt

 

200,989

 

195,612

 

Total liabilities

 

387,177

 

396,640

 

Commitment and contingencies

 

 

 

 

 

Equity:

 

 

 

 

 

Common stock

 

79

 

77

 

Additional paid-in capital

 

465,952

 

451,750

 

Accumulated other comprehensive income

 

154

 

1,815

 

Accumulated deficit

 

(389,703

)

(355,094

)

Total equity

 

76,482

 

98,548

 

Total liabilities and equity

 

$

463,659

 

$

495,188

 

 

6



 

Accuray Incorporated

Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes Depreciation

Amortization and Stock-Based Compensation (Adjusted EBITDA)

(in thousands)

(Unaudited)

 

 

 

Three Months Ended
March 31,

 

Nine Months Ended
March 31,

 

 

 

2015

 

2014

 

2015

 

2014

 

GAAP net loss

 

$

(2,967

)

$

(4,665

)

$

(34,609

)

$

(25,639

)

Amortization of intangibles (a) 

 

1,989

 

1,998

 

5,965

 

6,391

 

Depreciation (b) 

 

2,915

 

2,982

 

8,899

 

9,155

 

Stock-based compensation (c) 

 

3,377

 

3,260

 

10,504

 

8,243

 

Interest expense, net (d) 

 

4,051

 

3,366

 

12,062

 

10,013

 

Provision for income taxes

 

521

 

878

 

2,311

 

2,615

 

Adjusted EBITDA

 

$

9,886

 

$

7,819

 

$

5,132

 

$

10,778

 

 


(a) consists of amortization of intangibles - developed technology and distributor licenses

(b) consists of depreciation, primarily on property and equipment

(c) consists of stock-based compensation in accordance with ASC 718

(d) consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes

 

7



 

Accuray Incorporated

Reconciliation of Projected Net Loss to Forward-Looking Guidance for Non-GAAP Financial Measures

(in thousands)

(Unaudited)

 

 

 

Twelve Months Ending
June 30, 2015

 

 

 

From

 

To

 

GAAP net loss

 

$

(39,975

)

$

(36,975

)

Amortization of intangibles (a) 

 

8,000

 

8,000

 

Depreciation (b) 

 

11,775

 

11,775

 

Stock-based compensation (c) 

 

14,000

 

14,000

 

Interest expense, net (d) 

 

16,200

 

16,200

 

Provision for income taxes

 

3,000

 

3,000

 

Adjusted EBITDA

 

$

13,000

 

$

16,000

 

 


(a) consists of amortization of intangibles - developed technology and distributor licenses

(b) consists of depreciation, primarily on property and equipment

(c) consists of stock-based compensation in accordance with ASC 718

(d) consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes

 

8